Aurora is still waiting for its reward. This recent excerpt fron the WSJ (19th of Jan I think) suggests where it may go in the long run. Biotech analysis has so little credibility, and is so corrupt, that it will take a while for fund managers to recognize quality and growth, and for the righteous are rewarded... and ABSC will be among the righteous....
WSJ about the H&Q health-care conference.
"In most cases, investors liked small-cap stocks that would prove
vital to large pharmaceuticals companies that are expected to be
on a huge quest for new drugs in coming years to maintain
double-digit growth rates. "Unlike a few years ago, when
investors were looking at companies developing drugs purely,
now investors are looking for a lot more information companies
that aren't developing drugs, but aid in developing drugs cheaper
and faster," said Dennis Purcell, head of health-care investment
banking at H&Q.
Some of the most popular companies presenting at the
conference are involved in the new field of "functional genomics,"
the inelegant term for companies using huge volumes of newly
identified genetic data to test how new drugs or therapies will
alter the genes. Several investors cited
!!! Incyte Pharmaceuticals, ArQule and Aurora !!!
as their top picks for companies specializing
in various phases of such drug discovery.
Gary Gratny of Whelan & Gratny Capital Management lamented
missing Incyte's move to $43 from around $20 a year ago, but
others likened Incyte to Cisco Systems, a steady-growing stock
that is perennially accused of being overvalued." |
